Related Experiment Video
Updated: May 11, 2026
An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas
Published on: October 10, 2025
Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2
Karo Tanaka1, Ascia Eskin, Fabrice Chareyre
1Center for Neural Tumor Research and Section on Genetics of Hereditary Ear Disorders, House Research Institute, University of California, Los Angeles, CA 90057, USA.
Purpose:
The growth and survival of neurofibromatosis type 2 (NF2)-deficient cells are enhanced by the activation of multiple signaling pathways including ErbBs/IGF-1R/Met, PI3K/Akt, and Ras/Raf/Mek/Erk1/2. The chaperone protein HSP90 is essential for the stabilization of these signaling molecules. The aim of the study was to characterize the effect of HSP90 inhibition in various NF2-deficient models.
Experimental Design:
We tested efficacy of the small-molecule NXD30001, which has been shown to be a potent HSP90 inhibitor. The antiproliferative activity of NXD30001 was tested in NF2-deficient cell lines and in human primary schwannoma and meningioma cultures in vitro. The antitumor efficacy of HSP90 inhibition in vivo was verified in two allograft models and in one NF2 transgenic model. The underlying molecular alteration was further characterized by a global transcriptome approach.
Results:
NXD30001 induced degradation of client proteins in and suppressed proliferation of NF2-deficient cells. Differential expression analysis identified subsets of genes implicated in cell proliferation, cell survival, vascularization, and Schwann cell differentiation whose expression was altered by NXD30001 treatment. The results showed that NXD30001 in NF2-deficient schwannoma suppressed multiple pathways necessary for tumorigenesis.
Conclusions:
HSP90 inhibition showing significant antitumor activity against NF2-related tumor cells in vitro and in vivo represents a promising option for novel NF2 therapies.
Insights
HSP90 inhibition suppressed neurofibromatosis type 2 (NF2)-deficient cell proliferation and tumor growth. This targeted therapy shows promise for treating NF2-related tumors by disrupting essential signaling pathways.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Neurofibromatosis type 2 (NF2) cell growth relies on signaling pathways like PI3K/Akt and Ras/Raf/Mek/Erk1/2.
- Heat Shock Protein 90 (HSP90) stabilizes these crucial signaling molecules.
- Targeting HSP90 is a potential therapeutic strategy for NF2-deficient tumors.
Purpose of the Study:
- To investigate the therapeutic potential of HSP90 inhibition in NF2-deficient models.
- To characterize the molecular effects of HSP90 inhibition on NF2-related cells and tumors.
Main Methods:
- Tested NXD30001, a small-molecule HSP90 inhibitor, in NF2-deficient cell lines and primary human schwannoma/meningioma cultures.
- Evaluated antitumor efficacy in vivo using allograft and NF2 transgenic models.
- Utilized transcriptome analysis to understand molecular alterations.
Main Results:
- NXD30001 effectively degraded client proteins and inhibited proliferation in NF2-deficient cells.
- Gene expression analysis revealed NXD30001 altered pathways critical for proliferation, survival, vascularization, and Schwann cell differentiation.
- NXD30001 suppressed key tumorigenesis pathways in NF2-deficient schwannoma.
Conclusions:
- HSP90 inhibition demonstrates significant antitumor activity against NF2-related tumors both in vitro and in vivo.
- Targeting HSP90 presents a promising therapeutic avenue for novel NF2 treatments.
